Stock-Based Compensation for Moderna (MRNA)
Stock-Based Compensation for Moderna (MRNA): headline value $245.00M · YoY +12.6%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
MRNA
Currently viewingStock-Based CompensationSwitch metric
Latest period
$245.00M
YoY change
+12.6%
5Y CAGR
+39.0%
Peak year (2025)
$483.00M
Latest annual
$483.00M
Stock-Based Compensation history chart for Moderna (MRNA) from 2016 to 2025
Stock-Based Compensation history table for Moderna (MRNA) from 2016 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY |
|---|---|---|---|---|
| 2025 | $483.00M | +12.6% | ||
| 2024 | $429.00M | +40.7% | ||
| 2023 | $305.00M | +35.0% | ||
| 2022 | $226.00M | +59.2% | ||
| 2021 | $142.00M | +52.7% | ||
| 2020 | $93.00M | +14.6% | ||
| 2019 | $81.12M | +11.8% | ||
| 2018 | $72.56M | +81.2% | ||
| 2017 | $40.05M | +1.8% | ||
| 2016 | $39.36M | — |
Stock-Based Compensation values are taken from Moderna's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of Moderna (MRNA) stock-based compensation is $483.00M – grew 12.6% year-over-year.
Moderna stock-based compensation has recorded the values shown across consecutive periods, with a +39.0% compound annual growth rate over 2020–2025 (5 years).
The dataset's maximum stock-based compensation sits at $483.00M (2025); the minimum reading of $39.36M dates to 2016.
Moderna (MRNA) sits 5th of 8 Healthcare peers we track on this metric, against a peer median of $313.00M.
Moderna Stock-Based Compensation by Year
Moderna Stock-Based Compensation 2025: $483.00M
Moderna stock-based compensation in 2025 was $483.00M, grew 12.6% from 2024. This figure represents the highest annual value in the available history.
Moderna Stock-Based Compensation 2024: $429.00M
Moderna stock-based compensation in 2024 was $429.00M, surged 40.7% from 2023.
Moderna Stock-Based Compensation 2023: $305.00M
Moderna stock-based compensation in 2023 was $305.00M, surged 35.0% from 2022.
Moderna Stock-Based Compensation 2022: $226.00M
Moderna stock-based compensation in 2022 was $226.00M, surged 59.2% from 2021.
Moderna Stock-Based Compensation 2021: $142.00M
Moderna stock-based compensation in 2021 was $142.00M.
See more financial history for Moderna (MRNA).
Sector peers — Stock-Based Compensation
Companies in the same sector as Moderna, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $971.00M | Healthcare |
| AbbVie Inc. (ABBV) | $955.00M | Healthcare |
| Eli Lilly and Company (LLY) | $626.00M | Healthcare |
| AstraZeneca PLC (AZN) | $0 | Healthcare |
| Merck & Co., Inc. (MRK) | $0 | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
| Novo Nordisk A/S (NVO) | $0 | Healthcare |
Frequently asked questions
What is Moderna's stock-based compensation?
Latest reported stock-based compensation for Moderna (MRNA) is $245.00M (period ending December 31, 2025).
How has Moderna stock-based compensation changed year-over-year?
Moderna (MRNA) stock-based compensation changed +12.6% year-over-year on the latest annual filing.
What is the long-term growth rate of Moderna stock-based compensation?
Moderna (MRNA) stock-based compensation compound annual growth rate is +39.0% over the most recent 5 years available.
When did Moderna stock-based compensation hit its highest annual value?
Moderna stock-based compensation reached its highest annual value of $483.00M in 2025.
What was Moderna stock-based compensation in 2024?
Moderna (MRNA) stock-based compensation in 2024 was $429.00M.
What was Moderna stock-based compensation in 2025?
Moderna (MRNA) stock-based compensation in 2025 was $483.00M.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
MRNA Overview
Company profile, financial tools, and key metrics
MRNA Revenue Counter
Earns $61.61 every second. See per minute, hour, and day.
MRNA Earnings Counter
Loses −$89.49 per second. See per minute, hour, and day.
MRNA Economic Scale
Exceeds Timor-Leste's GDP. Compare with world economies.
MRNA What If Invested
What if you had invested $1,000? See historical returns from any date.
MRNA How It Makes Money
Discover visual breakdown of $1.94B in revenue — where it comes from and where it goes.
MRNA Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
MRNA Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
MRNA Daily Price Character
Explosive · 48.2% historical win rate (green days). Streaks & record days.
MRNA Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.